| Autor: |
Jong-Il Park, Seung-Jun Lee, Bum-Kee Hong, Yun-Hyeong Cho, Won-Yong Shin, Sang-Wook Lim, Woong-Chol Kang, Yongwhi Park, Sung-Yoon Lee, Yong-Joon Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Jung-Sun Kim, Jung-Hee Lee, Ung Kim, Sang-Wook Yangsoo Lim Jang, Yongwhi Young Hoon Park Jung, Kyoung Jin Kim, Soon-Jun Hong, Kyeong Ho Yun, Jung Ho Heo, Seung-Woon Rha, Woong Gil Choi, Wang Soo Lee Lee, Jinok Jung, Sunghoon Choi, Youn Haeng Cho, Woo Jung Park, Changhwan Youn, Seung Ho Hur, Hyun Hee Choi, Ju Han Kim, Hyun Kuk Kim, Yu-Jung Choi |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
eClinicalMedicine |
| Popis: |
BACKGROUND: Moderate-intensity statin role with ezetimibe combination therapy following percutaneous coronary intervention (PCI) has not been thoroughly investigated, particularly compared to high-intensity statin monotherapy. We aimed to investigate the effect of ezetimibe combination with moderate-intensity statin in patients with atherosclerotic cardiovascular disease following PCI. METHODS: This was a post-hoc analysis of a subset of patients who underwent PCI in the RACING trial. At 26 centres in South Korea, patients with atherosclerotic cardiovascular disease (ASCVD) were randomly assigned to receive either moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 10 mg with ezetimibe 10 mg) or high-intensity statin monotherapy (rosuvastatin 20 mg). The prespecified endpoints of the RACING trial were used. The primary endpoint was the 3-year composite of cardiovascular death, major cardiovascular events, and nonfatal stroke. Event rates between the two groups were compared using log-rank tests, and hazard ratios (HR) with 95% confidence intervals (CI) were estimated using Cox regression analysis. Consistent with the RACING trial, the primary and secondary efficacy endpoints were evaluated using an intention-to-treatment approach, and the safety endpoints were assessed in the safety population. The RACING trial was registered at ClinicalTrials.gov (NCT03044665). FINDINGS: Between Feb 14, 2017, and Dec 18, 2018, 3780 participants were enrolled in the RACING trial. Prior history of PCI was found in 2497 patients (67%, median 64 years, 79% male), and was associated with higher rates of the primary endpoint (hazard ratio [HR], 1.34; 95% confidence interval [CI], 1.06–1.69; p = 0.014). Among patients with prior PCI, moderate-intensity statin therapy with ezetimibe combination versus high-intensity statin therapy did not increase the risk of the primary endpoint (HR, 0.95; 95% CI, 0.74–1.24; p = 0.781). The proportion of patients with low-density lipoprotein cholesterol (LDL-C) |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
